Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...
A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback